MIRM Mirum Pharmaceuticals Inc

Price (delayed)

$18

Market cap

$548.16M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.91

Enterprise value

$511.45M

Highlights
The EPS has grown by 31% YoY but it has contracted by 20% from the previous quarter
The net income has plunged by 95% YoY and by 28% from the previous quarter
The quick ratio has dropped by 52% since the previous quarter and by 48% year-on-year

Key stats

What are the main financial stats of MIRM
Market
Shares outstanding
30.45M
Market cap
$548.16M
Enterprise value
$511.45M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.09
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$128.77M
EBITDA
-$128.12M
Free cash flow
-$96.06M
Per share
EPS
-$4.91
Free cash flow per share
-$3.19
Book value per share
$4.4
Revenue per share
$0
TBVPS
$7.38
Balance sheet
Total assets
$222.24M
Total liabilities
$88.36M
Debt
$53.97M
Equity
$133.88M
Working capital
$182.73M
Liquidity
Debt to equity
0.4
Current ratio
6.22
Quick ratio
6.09
Net debt/EBITDA
0.29
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-69.7%
Return on equity
-94.2%
Return on invested capital
-122.9%
Return on capital employed
-68.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MIRM stock price

How has the Mirum Pharmaceuticals stock price performed over time
Intraday
-0.22%
1 week
3.27%
1 month
3.93%
1 year
-0.83%
YTD
3.09%
QTD
-9.18%

Financial performance

How have Mirum Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$129.88M
Net income
-$132.49M
Gross margin
N/A
Net margin
N/A
The net income has plunged by 95% YoY and by 28% from the previous quarter
Mirum Pharmaceuticals's operating income has shrunk by 84% YoY and by 25% QoQ

Growth

What is Mirum Pharmaceuticals's growth rate over time

Valuation

What is Mirum Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.09
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 31% YoY but it has contracted by 20% from the previous quarter
Mirum Pharmaceuticals's equity has decreased by 22% from the previous quarter and by 14% YoY
MIRM's price to book (P/B) is 11% higher than its last 4 quarters average of 3.7

Efficiency

How efficient is Mirum Pharmaceuticals business performance
The ROIC has plunged by 75% YoY and by 7% from the previous quarter
Mirum Pharmaceuticals's return on assets has decreased by 49% YoY and by 20% QoQ
The ROE has decreased by 38% YoY and by 33% QoQ

Dividends

What is MIRM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MIRM.

Financial health

How did Mirum Pharmaceuticals financials performed over time
MIRM's total assets is 152% higher than its total liabilities
The quick ratio has dropped by 52% since the previous quarter and by 48% year-on-year
The company's current ratio has shrunk by 51% QoQ and by 48% YoY
The company's debt is 60% lower than its equity
The debt to equity has grown by 33% from the previous quarter
Mirum Pharmaceuticals's equity has decreased by 22% from the previous quarter and by 14% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.